kt-474
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 23, 2021 (NCT04772885)
Timeline
Indications
Mechanism of action
IRAK4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(=O)n(C2CCC(=O)NC2=O)c2cccc(C#CCOC3CCN(C[C@H]4CC[C@H](n5cc(NC(=O)c6cnn7ccc(N8C[C@H]9C[C@@H]8CO9)nc67)c(C(F)F)n5)CC4)CC3)c21- Mol. weight
- 865.94 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5569030 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06058156 | Phase 2 | Nov 9, 2023 | Kymera Therapeutics, Inc., Sanofi |
| NCT06028230 | Phase 2 | Sep 29, 2023 | Kymera Therapeutics, Inc., Sanofi |
| NCT04772885 | Phase 1 | Feb 23, 2021 | Kymera Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. | For profit | 3 | 1 | 2 | 2021 |
| Sanofi | For profit | 2 | 2 | 1 | 2023 |
2 organizations
Page 1 / 1